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SymptomsThis study investigated the clinical and neuropsychological correlates of N-acetyl aspartate (NAA)
concentration in the anterior cingulate cortex (ACC) in schizophrenia, and explored whether ACC NAA
concentration is sensitive to symptom change following cognitive behaviour therapy for psychosis (CBTp).
Participants comprised 30 patients and 15 healthy controls who underwent magnetic resonance spectroscopy
of the ACC and were assessed on frontal lobe based neuropsychological tasks. Twenty-four (of 30) patients
were followed-up; 11 subsequently received 8–9 months of CBTp in addition to standard care (CBTp+SC)
and 13 received SC only. At baseline (i) NAA and Cr concentrations were lower in patients compared to
controls, (ii) in patients, NAA concentration correlated inversely with positive symptoms and general
psychopathology (positive symptoms explained 21% of the variance; total variance explained=25%) and Cho
concentration correlated inverselywith positive symptoms, and (iii) in controls, NAA concentration correlated
positively with working and short-termmemory and Cr concentration inversely with executive function. NAA
concentration tended to increase in CBTp+SC patients at follow-up (n=7with usable data) concomitantwith
improvement in positive symptoms. NAA concentration may be more closely associated with symptoms and
symptom change than frontal lobe based neuropsychological function in schizophrenia, perhaps because the
latter is relatively stable during the long-term illness course.De Crespigny Park, London SE5
4 207 848 0860.
 CC BY license. © 2010 Elsevier Ireland Ltd. Open access under CC BY license. 1. Introduction
Schizophrenia is often characterised by a proﬁle of clinical and
neuropsychological impairment that is consistent with a frontal lobe
based pathology (Weinberger et al., 1994). Structurally, grey matter
(GM) reduction in the anterior cingulate cortex (ACC) has been
observed in patients with schizophrenia (Baiano et al., 2007; Fornito
et al., 2008), though such reductions are not limited to the ACC (see
Honea et al., 2005, for a meta-analytic review of GM reductions in
schizophrenia).
A further mode of investigating the neuropathology of schizo-
phrenia is at the neurochemical level. N-acetyl aspartate (NAA) loss
and impaired mitochondrial function are characteristic of several
neurodegenerative diseases, including Alzheimer's Disease and
multiple sclerosis (Perry et al., 2002; Rutten et al., 2003). Theseﬁndings suggest that NAA concentration may be an indicator of
mitochondrial function. N-methyl D-aspartate (NMDA) receptor
activation coupled with Ca2+ cellular inﬂux has been reported to
increase neuronal release of NAA and delay nerve cell death (Tranberg
et al., 2004). NAA concentration thus may also be an indicator of
NMDA function and neuronal longevity. Interestingly, NMDA gluta-
mate receptor dysfunction has been suggested to sub-serve many
abnormalities associated with schizophrenia (Moghaddam, 2003). It
has been reported that inhibitors of NMDA function, such as
phencyclidine or ketamine, precipitate symptoms of schizophrenia
in healthy people and exacerbate symptoms in patients with
schizophrenia (Adler et al., 1999; Krystal et al., 1994; Lahti et al.,
1995; Malhotra et al., 1997). Ketamine is also found to cause
disruptions in working memory in both healthy and schizophrenia
populations (Adler et al., 1999), indicating that deﬁcient activation of
NMDA receptors may be crucially involved in neuropsychological
deﬁcits commonly observed in patients with schizophrenia. Choline
(Cho) and creatine/phosphocreatine (Cr) concentrations may also be
important to neuronal integrity. Cho is involved in the synthesis of
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while Cr helps maintain the energy homeostasis within the nerve
cell (Andres et al., 2008). The evidence suggests that Cr may also
have direct effects on neuropsychological function. For example, oral
supplements of Cr increased intelligence, working memory perfor-
mance (Rae et al., 2003) and executive function (McMorris et al.,
2007, 2006).
Previous studies have reported, using magnetic resonance spec-
troscopy (MRS), lower ACC NAA level in patients with schizophrenia,
especially in those treated with typical antipsychotic drugs, compared
with healthy participants (Braus et al., 2002; Deicken et al., 2000;
Ende et al., 2000; Sanches et al., 2008; Tayoshi et al., 2009;Wood et al.,
2007; Yamasue et al., 2002; see Appendix A for detailed information).
Within this patient population, ACC NAA concentration is reported to
be inversely associated with illness duration in some studies (Braus
et al., 2002; Ende et al., 2000; Theberge et al., 2003), but not others
(Deicken et al., 1997; Tayoshi et al., 2009; Theberge et al., 2004;Wood
et al., 2007; Yamasue et al., 2002). NAA reductions have been reported
in antipsychotic drug-naïve ﬁrst-episode patients, and treatment may
increase NAA levels in both recent-onset cases and patients with
chronic illness (Braus et al., 2002; Fannon et al., 2003). NAA
concentration is positively associated with duration on atypical
antipsychotic medication in long-term patients (Braus et al., 2002),
and inversely correlated with the duration of positive symptoms in
ﬁrst-episode neuroleptic-naïve patients (Theberge et al., 2004). More
recently, Tayoshi et al. (2009) observed no association between NAA
concentration and symptoms, but reported a positive association
between NAA concentration andWisconsin Card Sorting Test (WCST)
performance; the latter ﬁnding was also present in two earlier studies
(Braus et al., 2002; Ohrmann et al., 2008).
Neuropsychologically, the ACC is involved in components of the
central executive that facilitate working memory (Osaka et al., 2004;
Smith and Jonides, 1999), including encoding of semantic information
(Kaneda and Osaka, 2008), and reported to be deactivated in
schizophrenia patients compared with healthy participants during
the stimulus encoding phase of a working memory task (Schlosser et
al., 2008). A further role of the ACC is in emotional decision-making,
where there is a relationship between an action and the reinforce-
ment value of its outcome (Rushworth et al., 2004; Walton et al.,
2007). The ACC is involved in updating and integrating recent
information to existing information on reward value of outcome in
terms of predicting future outcome (Behrens et al., 2007; Kennerley
et al., 2008).
The present study has two parts: cross-sectional and longitudinal.
Cross-sectionally, the study aimed to compare the ACC NAA
concentrations in patients with schizophrenia and healthy partici-
pants, and to determine their clinical and/or neuropsychological
correlates; it also explored these effects in Cho and Cr. All except for
three recent studies that examined these metabolites in patients with
schizophrenia (Ohrmann et al., 2008; Sanches et al., 2008; Tayoshi
et al., 2009) had a smaller sample size than that in our investigation,
and none undertook a comprehensive examination of metabolite
concentration relationships with clinical symptoms and neuropsy-
chological functions. We hypothesized that (1) NAA concentration
would be reduced in patients compared with healthy participants due
to impaired neuronal function; (2) in patients, NAA concentration
would be associated inversely with illness duration (Braus et al., 2002;
Ende et al., 2000; Theberge et al., 2003) and symptoms on the Positive
and Negative Syndrome Scale (Wood et al., 2007); and (3) NAA
concentration would be positively associated with neuropsycholog-
ical measures that involve the ACC, namely working memory, conﬂict
detection and decision-making (Behrens et al., 2007; Carter and van
Veen, 2007; Osaka et al., 2004; Peterson et al., 1999; Smith and
Jonides, 1999; Walton et al., 2007), both in healthy participants and
patients, though such relationships may be weaker in patients
because they, as mentioned earlier, engage the ACC at a less-than-normal level during relevant tasks. We expected that the clinical or
neuropsychological correlates of metabolite concentration would be
attenuated or abolished after controlling for ACC grey matter (GM)
concentration (Yamasue et al., 2002), as GM concentration may
inﬂuence metabolite availability.
Longitudinally, the study aimed to determine the effect of
cognitive behavioural therapy for psychosis (CBTp) on metabolite
concentration. A sub-sample of the patients in the present investiga-
tion went on to receive CBTp in addition to their standard care. The
study therefore also examined whether (i) baseline metabolite
concentration predicted symptom change following CBTp+SC and
(ii) there was a change in metabolite concentration in patients who
received CBTp in addition to standard care. We hypothesized that in
this sub-sample, NAA concentration would increase coincident with a
reduced level of symptoms following CBTp.
2. Materials and method
2.1. Participants and design
The study involved 30 patients with schizophrenia and 15 healthy
participants, all of whom underwent MRS of the ACC at study entry.
The patient and control groups were matched on average for age and
gender (Table 2). All patients were assessed by a Consultant
Psychiatrist (DF) for clinical diagnosis using the Structured Clinical
Interview for DSM-IV Axis I disorder (First et al., 2002) and symptom
severity using the Positive and Negative Syndrome Scale (PANSS, Kay
et al., 1987). All patients were recruited from the South London and
Maudsley NHS Foundation Trust as part of a larger project investi-
gating the functional neuroimaging correlates and predictors of CBTp
(the MRS component was added to the larger project), had been on
stable doses of antipsychotic medication for at least 2 years, and on
the current antipsychotic drug for at least 3months before taking part.
Of the 30 patients at study entry (baseline), 11 patients sub-
sequently received CBTp+SC in a specialist clinical service [Psycho-
logical Interventions Clinic for Outpatients with Psychosis (PICuP),
South London and Maudsley NHS Foundation Trust (SLAM)] in
addition to their standard care, and 13 patients continued to receive
standard care only (SC controls); all of these 24 patients (i) received a
rating of ≥60 on the PANSS, (ii) reported at least one positive
‘distressing’ symptom of schizophrenia, and (iii) wished to receive
CBTp (if available: only about 10–20% of eligible SLAM patients were
accepted for CBTp with the existing resources; availability was the
only criterion that determined whether or not eligible patients
received CBTp). Eight of 11 CBTp+SC patients and 12 of 13 SC
control patients were assessed for symptom severity at follow-up, of
whom seven and four patients, respectively, underwent MRS at
follow-up. Six (of 30) patients had low symptom severity at baseline;
they were considered to be responsive to antipsychotic treatment by
their long-term treating clinicians (SC responsive); these patients
were not followed up.
The patients in the CBTp+SC and SC control groups were
recruited from the same geographical area, were identiﬁed by local
Consultant Psychiatrists as suitable for CBTp, and wished to receive
CBTp in addition to their usual care. Allocation to CBTp+SC and SC
control groups was not randomised, but followed a cohort case-
controlled design. Patients who were referred to and accepted for
CBTp by the Psychological Interventions Clinic for Outpatients
with Psychosis (PICuP), SLAM NHS Foundation Trust went into the
CBTp+SC group. Others who matched demographically (age and
number of years in education) and clinically (illness duration and
PANSS symptoms) as much as possible those accepted for CBTp by
the PICuP were studied as part of the SC control group over the
same interval as the CBTp+SC group patients. SC consisted of case
management offered by the case management team for a particular
geographical area. Most patients (80%) were on a single antipsychotic
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took aripiprazole and a further patient also took triﬂuoperazine. Of the
six patients on clozapine, one patient also took quetiapine and a
further patient also took amisulperide. Of the two patients on
haloperidol, one patient was also on sulperide and the other patient
on pipotiazine. In addition to antipsychotic drug treatment, four
patients were receiving anti-cholinergics.
CBTp followed the procedure developed by Fowler et al. (1995).
Therapy sessions were conducted on a weekly or fortnightly basis, as
preferred by the patient. Patients received an average of 16 sessions.
All CBT interventions were formulation-driven, and focused on the
therapy goals of the patient. The therapists were supervised by one of
the investigators (EK) who has extensive experience of CBTp.
The study procedures were approved by the ethics committee of
the Institute of Psychiatry and the South London and Maudsley NHS
Foundation Trust, London. All participants provided written informed
consent to their participation and were compensated for their time
and travel.
2.2. Neuropsychological assessments
All patients and 13 healthy participants were assessed on
neuropsychological measures (described in Table 1) that are
considered to recruit the ACC and found to reveal performance
deﬁcits in executive function, working/short-term memory, attention
and emotional decision-making in schizophrenia.
2.3. Magnetic resonance spectroscopy: data acquisition and processing
Images were acquired using a 1.5 Tesla GE N/Vi Signa System
(General Electric, Milwaukee, WI, USA) at the Maudsley Hospital,
South London. A quadrature birdcage head coil was used for RF
transmission and reception. Initially, a series of fast gradient echo
scout images were acquired in order to orient subsequent images
relative to the anterior commissure/posterior commissure line and
the interhemispheric ﬁssure. Subsequently, the whole brain was
scanned with a 3-D inversion recovery prepared fast spoiled GRASS
T1-weighted dataset. Chemical shift images were acquired from a
PRESS excited volume in a 1.5 cm thick slab through the anterior
commissure, correspondingwith the dorsal ACC, with a nominal voxel
size of 1.5 cm3 (24×24 phase-encode steps over a 24 cm FOV). To
minimise relaxation effects, a short TE of 35 ms was used, and a
relatively long TR of 2 s.
Only metabolite information with a ﬁtting error (percent standard
deviation) of b20% was included in the ﬁnal analysis (Ohrmann et al.,Table 1
Battery of neuropsychological measures.
Neuropsychological test Variables used in analysis
Executive function
Brixton Test (Burgess and Shallice, 1997) Perseverative errors
Wisconsin Card Sorting Test (WCST)
(Heaton et al., 1993)
Perseverative errors
Working/short-term memory
Letter number test (Gold et al., 1997) Total number of items correct
Wechsler Memory Scale—Revised (WMS-R) Logical
Memory (Wechsler, 1987)—Immediate recall
Unit recall scaled score
Hopkins Verbal Learning Test
(Shapiro et al., 1999)
Total number of items freely
recalled
Attention
Continuous Performance Test—identical pairs
(Cornblatt et al., 1988)
Discriminability
Emotional decision-making
Iowa Gambling Task (Bechara et al., 1994) Overall learning
(block 5 minus block 1)2008). Absolute concentrations of NAA, Cho and Cr were measured in
millimolars in all participants using the LCmodel (McLean et al., 2000;
Provencher, 1993). For each MRS voxel, the proportions of GM, white
matter and cerebrospinal ﬂuid (CSF) were calculated by segmenting
the Spoiled Gradient Recalled (SPGR) image (Fig. 1). This allows
correction for CSF contamination within each voxel and extrapolation
to concentrations for pure GM (McLean et al., 2000). Metabolite
concentration was calculated as a function of CSF concentration
within each voxel using the following formula,
Metabolite value=
ð1−CSF concentrationÞ
100
NAA, Cho and Cr absolute concentration estimates in millimolars
are reported rather than metabolite peak ratios, such as NAA/Cho,
NAA/Cr and Cho/Cr, because absolute concentrations of individual
metabolites are not inﬂuenced by ﬂuctuations in the concentration of
the reference metabolite. Metabolite ratios are believed to account for
alterations in the Cr reference peak which invalidate its usefulness as
an internal reference for the other metabolite peaks of the proton
spectrum (Deicken et al., 1997).
2.4. Statistical analysis
2.4.1. Cross-sectional analysis
2.4.1.1. Group comparison of metabolite concentration. Differences
between patient (across all patients) and healthy participant groups
in metabolite concentration and GM concentration, age, years of
education, and clinical and neuropsychological variables were
examined using analysis of variance (ANOVA). For the neuropsycho-
logical variables showing a non-normal distribution (Brixton persev-
erative errors), Mann–Whitney U tests were performed. A chi-
squared test examined group differences in gender distribution.
2.4.1.2. Clinical correlates of metabolite concentration. Pearson and
partial correlations controlling for GM concentration, or Spearman
correlations for clinical variables with a non-normal distribution
(antipsychotic medication level), were performed between clinical
variables and metabolite concentrations. The clinical variables wereFig. 1. A Spoiled Gradient Recalled (SPGR) brain image in the axial slice in a control
subject. The square indicates the volume of interest (VOI), 1.5×1.5×1.5 cm3 voxel in
the anterior cingulate cortex. Within the VOI, each tissue (cerebrospinal ﬂuid, grey
matter and white matter) was segmented.
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the age at onset of psychotic symptoms as reported by the patient and
where possible conﬁrmed with other sources and age at the time of
baseline assessments) and antipsychotic medication level (in chlor-
promazine equivalents). Spearman correlations were performed to
examine the relationship between metabolite values and individual
PANSS items in those subscales that were found to have a signiﬁcant
association with metabolite values.
2.4.1.3. Neuropsychological correlates of metabolite concentration.
Pearson and partial correlations controlling for GM concentration, or
Spearman correlations for neuropsychological variables with a non-
normal distribution (Brixton perseverative errors), were performed
between neuropsychological performance measures and metabolite
concentration in patient and healthy participant groups.
2.4.1.4. Multiple regression of clinical and/or neuropsychological correlates
on metabolite concentration. Signiﬁcant clinical and/or neuropsycholog-
ical variables that had a normal distribution were entered into the
multiple regression model using a stepwise method (to estimate the
effect of individual predictors on variability of criterion variable) and
using a forced-entry method (to explain the combined effect of
predictors on the variability of the criterion variable).
2.4.2. Longitudinal analysis
2.4.2.1. Group comparison of metabolite concentration. Due to the small
sample sizes, differences between CBTp+SC, SC control and SC
responsive patient groups in age, education, clinical variables, and
baseline metabolite and GM concentrations were examined using non-
parametric analyses, namely the Kruskal-Wallis test. A chi-squared test
determined group differences in gender distribution.
2.4.2.2. Metabolite concentration as a predictor of symptom change
following CBTp.Spearman correlationswere performed in the CBTp+SC
patients who were followed up (n=8) between baseline metabolite
concentrations and residual PANSS symptom change scores from
baseline to follow-up.
2.4.2.3. Change in symptom severity and metabolite concentration
following CBTp. Due to the small sample sizes (CBTp+SC, n=7; and
SC control, n=4), changes in symptom severity, metabolite and GM
concentrations from baseline to follow-up in the patient groups were
examined using the Wilcoxon Signed Rank test.
All analyses were performed in SPSS windows (version 15). Alpha
level for testing signiﬁcance of effects was maintained at Pb0.05. We
chose not to apply the Bonferroni method of adjusting the P value
because we expected the size of the relationship between MRS values
and symptoms/neuropsychological functions to be small or at best
modest given that symptoms in schizophrenia are unlikely to have a
single aetiology and successful task performance on most neuropsy-
chological tasks would recruit additional brain regions.
3. Results
3.1. Cross-sectional analysis
3.1.1. Group differences in demographic and neuropsychological variables
Patient and healthy participant groups did not differ in gender and
age. Patients had fewer years in education and showed deﬁcient
performance on most neuropsychological measures relative to
healthy participants (Table 2).
3.1.2. Group differences in metabolite concentration in the ACC
NAA, Cr and GM concentrations were lower in the patient
compared with the healthy participant group (Table 3).3.1.3. Clinical correlates of metabolite concentration
NAA concentration correlated inversely with positive symptoms,
general psychopathology and total symptoms (Table 4). These
correlations remained signiﬁcant after controlling for GM. NAA
concentration correlated inversely with negative symptoms only
after controlling for GM. PANSS item-wise correlations revealed that
NAA concentration was inversely correlated with delusions, disorga-
nisation and persecution items of the positive syndrome subscale,
passive social withdrawal and stereotyped thinking items of the
negative syndrome subscale, and somatic concern and preoccupation
items of the general psychopathology subscale.
Cho concentration correlated inversely with positive and total
symptoms. After controlling for GM concentration, Cho concentration
correlated with total symptoms, but not positive symptoms. Cho
concentration correlated inversely with negative symptoms at a trend
level only after controlling for GM concentration. PANSS item-wise
correlations revealed that Cho concentration was inversely correlated
with disorganisation and hostility items of the positive syndrome
subscale, passive social withdrawal item of the negative syndrome
subscale, and somatic concern item of the general psychopathology
subscale. Cho concentration correlated positively with antipsychotic
medication dosage. Cr concentration did not correlate with any
clinical variable.3.1.4. Neuropsychological correlates of metabolite concentration
Patients: A positive correlation between NAA concentration and
working memory as assessed by the letter number test emerged only
after controlling for GM concentration (Table 5).
Healthy participants: NAA concentration correlated positively with
working memory as assessed by the letter number test and short-
term memory as assessed by the Hopkins verbal learning test, though
these correlations were reduced to a trend level of signiﬁcance after
controlling for GM concentration (Table 5). Cho concentration
correlated inversely with short-term memory as assessed by the
Wechsler Memory Scale—Revised (WMS-R) logical memory imme-
diate recall test after controlling for GM concentration. Cr concentra-
tion correlated inversely with executive function as assessed by
Brixton perseverative errors.3.1.5. Multiple regression of clinical and/or neuropsychological
correlates of metabolite concentration
Patients: In the stepwise regression model with NAA concentra-
tion as the criterion variable, positive symptoms proved to be a
signiﬁcant predictor (r=−0.489, P=0.006). The model explained 21%
of the variance in NAA concentration. In the forced-entry regression
model, the predictors (positive symptoms, general psychopathology
and letter number test) explained 25% of the variance in NAA
concentration.
Healthy participants: In the stepwise regression model with NAA
concentration as the criterion variable, short-term memory as
assessed by the Hopkins verbal learning test was a signiﬁcant
predictor (r=0.576, P=0.039). The model explained 27% of the
variance in NAA concentration. In the forced-entry regression model,
the predictors (Hopkins verbal learning test and letter number test)
explained 27% of the model.3.2. Longitudinal analysis
3.2.1. Metabolite concentration differences at baseline between patient
sub-groups
NAA concentration tended to differ between patient groups at
baseline mainly due to greater concentration in the low-symptom
SC-responsive group (Table 6).
Table 2
Demographic, clinical and neuropsychological characteristics of patients and healthy participants groups.
Characteristic Patients Healthy participants Test χ2 (df) P
Gender: male/female (n) 24/6 13/2 Chi-squared 0.304 (1) 0.581
mean, S.D. mean, S.D. F or z (df)
Age in years 36.40, 8.64 35.40, 13.34 ANOVA 0.092 (1,43) 0.763
Years in education 13.83, 2.15 15.61, 3.23 ANOVA 4.555 (1,41) 0.039
Illness duration, years 12.98 8.94
Symptoms (PANSS)
Positive 16.93, 3.95
Negative 17.87, 4.52
General psychopathology 31.70, 6.39
Total 66.50, 13.17
Medication level (chlorpromazine equivalents) 502.67, 327.88
Medication type (n)
Olanzapine 12
Clozapine 6
Risperidone 5
Aripiprazole 2
Flupentixol 2
Amisulperide 1
Haloperidol 2
Neuropsychological function
Brixton perseverative errors 0.50, 0.78 0.31, 0.48 Mann–Whitney U −0.552 (1,41) 0.648
WCST perseverative errors 18.17, 8.86 11.75, 7.51 ANOVA 4.870 (1,40) 0.033
Letter number test number correct 13.80, 3.80 16.92, 2.96 ANOVA 6.925 (1,41) 0.012
WMS logical memory immediate unit recalled 7.10, 2.58 9.69, 3.33 ANOVA 7.533 (1,40) 0.009
Hopkins total freely recalled 21.86, 5.38 26.92, 5.17 ANOVA 8.122 (1,40) 0.007
CPT discriminability 0.29, 0.59 1.87, 1.00 ANOVA 14.257 (1,39) 0.001
IGT overall learning 2.80, 11.83 8.92, 14.73 ANOVA 2.092 (1,41) 0.156
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CBTp
In the CBTp+SC group, metabolite concentration at baseline was
not associated with symptom change following CBTp (Supplementary
Table).
3.4. Symptom severity and metabolite concentration change from
baseline to follow-up in CBTp+SC and SC control groups
Positive symptoms improved following CBTp in the CBTp+SC
group, while negative symptoms tended to deteriorate in the SC
control group (Table 7).
NAA concentration tended to increase in the CBTp+SC group from
baseline to follow-up (Table 7).
4. Discussion
The present investigation examined the concentrations of NAA,
Cho and Cr in the ACC and their clinical and neuropsychological
correlates in patients with schizophrenia and healthy participants
(cross-sectional investigation). The study also explored whether
baseline metabolite concentration predicted symptom change fol-
lowing CBTp+SC and whether a reduction in symptoms following
CBTp+SC was accompanied by higher NAA concentration relative to
baseline (longitudinal investigation).Table 3
ACCmetabolite and greymatter concentrations (mean, S.D.) at baseline at each voxel in
patients and healthy participants.
CSI variable
(millimolars)
Patient
(n=30)
Healthy participants
(n=15)
F (p)
NAA 7.42, 1.26 8.56, 1.39 7.682 (0.008)
Cho 1.90, 0.38 1.99, 0.36 0.654 (0.423)
Cr 7.03, 1.24 7.89, 1.02 5.345 (0.026)
Grey matter 53.99, 10.51 61.39, 8.58 5.549 (0.023)4.1. Summary of clinical and neuropsychological correlates of metabolite
concentration (cross-sectional investigation)
The major ﬁndings from the cross-sectional analysis were that in
patients: (1) NAA concentration was reduced compared to healthy
participants, (2) greaterNAA concentrationwas associatedwith a lower
level of positive symptoms, general psychopathology and better
working memory (positive symptoms alone explained 21% of the
variance; total variance explained=25%), and (3) greater Cho concen-
tration was associated with a lower level of positive symptoms and
higher level of antipsychotic medication. In healthy participants the
following associationswere observed: (1) NAA concentration positively
with working and short-termmemory, (2) Cho concentration inversely
with short-term memory, and (3) Cr concentration inversely with
executive function. These ﬁndings will be discussed in turn.
4.1.1. Clinical correlates of metabolite concentrations
The ﬁndings of lower ACC NAA concentration in schizophrenia
patients (Deicken et al., 1997; Ende et al., 2000; Wood et al., 2007)
and clinical correlates of NAA concentration support previous
evidence (Theberge et al., 2003; Wood et al., 2007; Yamasue et al.,
2002). Our study of a relatively larger sample of patients than most
previous studies is the ﬁrst to observe that NAA concentration was
inversely associated with the severity of positive, negative and
general psychopathology symptoms based on the three-dimensional
model of the PANSS (Kay et al., 1987). Twenty percent of our patients
were SC treatment responsive, giving a wider range to symptom
scores than earlier studies. Patients who had low symptom severity
and were considered to have responded sufﬁciently to their standard
(mostly atypical) antipsychotic treatment tended to show greater
NAA concentration than patients who were symptomatic (baseline
comparisons), suggesting that NAA concentration may vary as a
function of symptom severity and treatment response.
NAA concentration being a by-product of neurotransmitter turn-
over (Tranberg et al., 2004), the symptom severity-metabolite concen-
tration associations may reﬂect the efﬁciency of neurotransmission. As
noted in Section 1, NAA concentration may be an indicator of NMDA
Table 4
Clinical correlates of metabolite concentration at baseline (patients only).
NAA concentration Cho concentration Cr concentration
r or ρ r (P) rp1 (P) r (P) rp1 (P) r (P) rp1 (P)
Illness duration r −0.059 (0.756) 0.091 (0.640) −0.064 (0.735) 0.045 (0.817) −0.291 (0.118) −0.244 (0.203)
Antipsychotic medication level Rho 0.197 (0.298) 0.442 (0.014) 0.073 (0.700)
Symptoms (PANSS)
Positive (P) symptoms r −0.489 (0.006) −0.430 (0.020) −0.391 (0.033) −0.325 (0.085) −0.308 (0.098) −0.262 (0.170)
Negative (N) symptoms r −0.297 (0.111) −0.418 (0.024) −0.287 (0.124) −0.366 (0.051) −0.211 (0.264) −0.262 (0.170)
General psychopathology (GP) r −0.416 (0.022) −0.506 (0.005) −0.299 (0.109) −0.341 (0.070) −0.204 (0.281) −0.219 (0.254)
Total r −0.450 (0.013) −0.512 (0.004) −0.361 (0.050) −0.384 (0.040) −0.263 (0.160) −0.266 (0.163)
Individual symptoms
Delusions (P) Rho −0.411 (0.024) −0.342 (0.064) −0.192 (0.309)
Disorganisation (P) Rho −0.525 (0.003) −0.369 (0.045) −0.136 (0.475)
Persecution (P) Rho −0.390 (0.033) −0.193 (0.307) −0.068 (0.719)
Hostility (P) Rho 0.062 (0.745) 0.370 (0.044) 0.163 (0.390)
Passive social withdrawal (N) Rho −0.370 (0.044) −0.393 (0.032) −0.261 (0.163)
Stereotyped thinking (N) Rho −0.422 (0.020) −0.073 (0.684) −0.221 (0.240)
Somatic concern (GP) Rho −0.419 (0.021) −0.407 (0.026) −0.129 (0.496)
Preoccupation (GP) Rho −0.528 (0.003) −0.201 (0.287) −0.264 (0.156)
rp
1: partial correlation controlling for GM concentration; P: PANSS positive symptom subscale; N: PANSS negative symptom subscale; GP: PANSS general psychopathology subscale.
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a delayed response to sudden non-physiological decrease in extracel-
lular osmolarity and high K+intra-cellular and NMDA activation
(Tranberg et al., 2007). Elevated concentration of NAA in the ACC in
schizophrenia patients with lower level of symptoms may reﬂect
increased turnover of neurotransmitters such as dopamine and NMDA.
Similarly, the association between Cho concentration and total and
positive symptoms may also reﬂect improved neurotransmitter
function and neuronal integrity with milder symptoms. The Cho peak
includes solublemembranephospholipids includingphosphorylcholine
(PCho), glycerophosphocholine (GPCho) and a relatively negligible
amount of free choline (Ross and Sachdev, 2004). PCho is involved in
synthesis of the insoluble membrane phospholipids, while GPCho is a
product of membrane degradation, and free choline is involved in
synthesis of the neurotransmitter acetylcholine, aswell as inmembrane
synthesis (Ross and Sachdev, 2004). An increase in the Cho peak is
associated with an increase in membrane breakdown or turnover and
myelination (Ross and Sachdev, 2004). The positive association
between antipsychotic medication dosage and Cho concentration, a
measure of neuronalmembrane turnover (Miller, 1991; Ohrmann et al.,
2008), suggests that medication level also inﬂuences neuronal activity.
4.1.2. Neuropsychological correlates of metabolite concentration
In patients, the ﬁnding of an association between greater NAA
concentration and better working memory supports evidence for theTable 5
Neuropsychological correlates of metabolite concentration at baseline in patients and healt
Neuropsychological function Group N r or rho NAA concentration
r or rho rp1 (P)
Brixton perseverative errors Patient 30 Rho 0.180 (0.341)
Control 13 Rho 0.356 (0.232)
WCST perseverative errors Patient 30 r −0.097 (0.610) −0.13
Control 12 r 0.271 (0.394) 0.24
Letter–number test number correct Patient 30 r 0.303 (0.104) 0.37
Control 13 r 0.557 (0.048) 0.52
WMS logical memory immediate
unit recalled
Patient 29 r 0.301 (0.112) 0.33
Control 13 r 0.330 (0.271) 0.27
Hopkins verbal learning test total
number freely recalled
Patient 29 r 0.127 (0.512) 0.11
Control 13 r 0.576 (0.039) 0.55
CPT discriminability Patient 29 r −0.037 (0.848) 0.15
Control 12 r 0.329 (0.297) 0.27
IGT overall learning Patient 30 r 0.179 (0.343) 0.21
Control 13 r 0.042 (0.892) 0.07
rp
1: partial correlation controlling for GM concentration.role of frontal lobe function in working memory using functional MRI
and proton MRS in schizophrenia (Bertolino et al., 2000; Callicott
et al., 2000; Ohrmann et al., 2007), although this association explained
only a very small amount (3%) of the variance in NAA concentration
that was additional to that explained by positive symptoms.
In the healthy group, greater NAA concentration was associated
with better working and short-term memory. The ACC is activated
during both working and short-term memory (Kim et al., 2006;
Lenartowicz and McIntosh, 2005). NAA concentration in the frontal
lobe white matter was positively associated with working memory in
healthy children, which may be related to increased number of
dendritic processes at an early age (Yeo et al., 2000). NAA con-
centration has a role in neuronal integrity in the form of increased
myelination and mitochondrial function (Ross and Sachdev, 2004)
and this may facilitate working and short-term memory.
Greater Cho concentration correlated inversely with short-term
memory in the healthy group when controlling for GM concentration
in the ACC. A negative association between Cho concentration in the
occipito-parietal white matter and IQ, independent of the positive
association between NAA concentration and IQ, in healthy individuals
has been previously reported (Jung et al., 1999). Our ﬁndings suggest
independentmetabolite concentration-neuropsychological associations
between NAA, Cho and Cr in healthy individuals. Greater Cr concentra-
tionwas associatedwith poorer executive function in the present study.
A study of elderly males found negative correlations between adjustedhy participants.
Cho concentration Cr concentration
r or rho rp1 (P) r or rho rp1 (P)
−0.198 (0.293) 0.331 (0.074)
0.356 (0.232) 0.579 (0.038)
9 (0.473) −0.011 (0.956) −0.030 (0.877) −0.102 (0.592) −0.116 (0.550)
8 (0.461) 0.390 (0.211) 0.368 (0.265) −0.225 (0.483) 0.312 (0.35)
9 (0.043) −0.163 (0.388) −0.160 (0.407) −0.130 (0.493) −0.124 (0.523)
9 (0.077) 0.011 (0.971) −0.083 (0.797) 0.156 (0.611) −0.030 (0.927)
1 (0.085) 0.054 (0.781) 0.045 (0.822) −0.017 (0.932) −0.025 (0.898)
8 (0.382) −0.453 (0.120) −0.610 (0.035) −0.022 (0.946) −0.267 (0.401)
9 (0.564) 0.181 (0.348) 0.177 (0.369) 0.269 (0.159) 0.265 (0.173)
5 (0.061) −0.173 (0.572) −0.330 (0.295) 0.277 (0.36) 0.061 (0.851)
8 (0.423) −0.114 (0.555) 0.016 (0.936) 0.003 (0.986) 0.088 (0.656)
5 (0.413) −0.209 (0.514) −0.346 (0.297) 0.207 (0.519) 0.006 (0.986)
0 (0.273) 0.026 (0.891) 0.029 (0.879) 0.062 (0.747) 0.064 (0.742)
8 (0.811) −0.063 (0.839) −0.025 (0.939) −0.225 (0.461) −0.169 (0.600)
Table 6
Demographic, clinical and metabolite concentration characteristics at baseline of CBTp+SC (n=11), SC control (n=13), and SC responsive (n=6) patients.
Characteristic CBTp+SC SC control SC responsive χ2 P
Gender: male/female (n) 6/5 12/1 6/0 7.185 0.028
mean, S.D. mean, S.D.
Age in years 34.64, 8.62 37.46, 8.77 37.33, 9.42 0.745 0.689
Years in education 14.45, 2.46 13.46, 1.76 13.77, 2.4 1.156 0.561
Illness duration, years 11.94, 8.60 13.77, 9.70 13.17, 9.28 0.303 0.860
Symptoms (PANSS)
Positive 17.45, 2.95 19.15, 2.64 11.17, 1.72 14.644 0.001
Negative 18.18, 4.98 19.23, 3.86 14.33, 3.61 5.779 0.056
General psychopathology 32.27, 6.75 34.0, 5.49 25.67, 3.83 6.775 0.034
Total 67.91, 12.87 72.39, 9.94 51.17, 7.78 9.512 0.009
Medication level 564.42, 303.17 500.55, 394.78 394.05, 207.59 1.787 0.409
Metabolite concentration
NAA 7.65, 0.92 6.85, 1.43 8.23, 0.91 5.313 0.070
Cho 1.92, 0.60 1.86, 0.24 1.94, 0.18 0.493 0.781
Cr 6.89, 1.40 6.87, 0.95 7.48, 1.60 1.047 0.592
Grey matter 57.66, 10.71 51.17, 11.36 53.37, 7.14 1.096 0.578
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memory and verbal memory (Ferguson et al., 2002). The study did not
include ameasure of executive function. Ferguson et al. (2002) believed
that the ﬁndings ﬁt with evidence that higher Cr levels are associated
with cognitive ageing. They proposed that poorer neuropsychological
performance in healthy ageing is associated with an increase in
Phosphocreatine (PCr) due to a reduction in conversion of PCr to
Adenosine-tri-phosphate (ATP) for energy. Increased Cr concentration
may be a marker of decreased brain energy metabolism.
4.2. Effect of cognitive behaviour therapy for psychosis on metabolite
concentration
Our preliminary investigation of change in metabolite concentra-
tion in a small number of patients who received CBTp+SC compared
to patients who received SC only revealed a trend for an increase in
NAA concentration with CBTp. This increase in NAA was concomitant
with improvement in positive symptoms in CBTp+SC patients. This
ﬁnding is consistent with the view that NAA concentration increases
with alleviation of symptoms as discussed above. Recent functional
imaging studies also provide evidence for a role of the ACC in
responsiveness to CBT in psychosis (Kumari et al., 2009) as well as
major depression (Costafreda et al., 2009).
4.3. Limitations and future research
One of the limitations of the study was that the sample sizes of
patients who received CBTp+SC or SC only and were clinically
assessed and/or scanned at follow-up were small. A further limitation
was that gender distribution differed between the patient groups.
Although there was no gender effect within each patient group in theTable 7
Symptoms, metabolite and grey matter concentration (mean, S.D.) at baseline and follow-u
CSI variable Baseline CBTp+SC (n=7) z (P)
FOLLOW-UP
Clinical symptoms
Positive symptoms 18.14 (2.34) 15.67 (3.50) −2.0
Negative symptoms 18.57 (5.71) 15.67 (2.34) −0.8
General psychopathology 32.00 (5.66) 27.33 (4.97) −1.3
Total symptoms 68.71 (12.27) 58.67 (10.17) −1.4
Metabolite concentration
NAA 7.65 (0.68) 8.31 (0.77) −1.8
Cho 1.85 (0.42) 1.93 (0.2) −0.5
Cr 6.79 (0.89) 7.25 (1.03) −0.8
Grey matter 57.06 (11.55) 58.60 (8.51) −0.3metabolite concentrations in the present study, higher ACC glutamine
level in male compared to female schizophrenia patients has been
previously observed (Tayoshi et al., 2009). Other effects of gender on
ACC function have also been reported, for example, reduced ACC
glucose metabolism in male chronic patients relative to healthy
participants and female patients (Fujimoto et al., 2007). The
predictive value of NAA concentration on symptom change in patients
receiving psychological treatment or standard care needs to be
examined in a larger sample involving a sufﬁcient number of both
men and women with schizophrenia. Additionally, the role of clinical
and neuropsychological variables on ACC NAA levels in patients who
improve with CBTp needs to be explored.
4.4. Conclusions
Higher NAA and Cho concentrations in the ACC in patients are
associated with lower symptom severity. Stronger and more
consistent associations between metabolite concentrations and
symptom severity than neuropsychological function suggest that
metabolite concentration and symptoms may co-ﬂuctuate more
strongly. Neuropsychological deﬁcits may be more stable (Szoke
et al., 2008) and not necessarily improve in parallel with symptom
improvement (Hughes et al., 2003). NAA concentration may yet
reﬂect symptom changes following CBTp and, if replicated in future
studies, has the potential to provide a useful biological marker of
clinical response to psychological treatments.
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Baseline SC control (n=4) z (P)
FOLLOW-UP
32 (0.042) 19.25 (2.22) 18.25 (2.63) −0.365 (0.715)
13 (0.416) 18.75 (4.99) 22.00 (6.16) −1.841 (0.066)
82 (0.167) 35.00 (6.68) 32.75 (5.91) −0.535 (0.593)
72 (0.141) 73.00 (10.42) 73.00 (13.64) −0.001 (1.000)
59 (0.063) 7.40 (0.69) 7.04 (0.38) −1.826 (0.068)
07 (0.612) 1.90 (0.18) 2.01 (0.08) −0.730 (0.465)
45 (0.398) 7.02 (0.16) 7.36 (0.99) −0.730 (0.465)
38 (0.735) 53.53 (5.49) 53.24 (3.35) −0.365 (0.715)
Appendix A. Summary of magnetic resonance spectroscopy studies on the anterior cingulate cortex (ACC) in schizophrenia patients
Publication Participants Measures Results
Deicken et al. (1997) Schizophrenia patients
(n=26; 9 on atypical and 17 on typical)
Healthy participants (n=16)
NAA, Cho and Cr, illness duration,
antipsychotic medication dose
Patients had lower NAA concentration
compared to healthy participants. No
signiﬁcant group differences or lateralized
asymmetries for Cho or Cr. No signiﬁcant
correlations between NAA and either
illness duration or antipsychotic
medication dose.
Ende et al. (2000) Schizophrenia patients
(n=19; 10 on atypical and 9 on typical)
Healthy participants (n=16)
NAA, Cho and Cr, age, illness
duration.
Patients had lower NAA concentration
compared to healthy participants.
Patients receiving typical medication
(but not atypical) had lower NAA
concentration than healthy participants.
NAA concentration was inversely
correlated with age in patients and
healthy participants, and with illness
duration (corrected for age) in patients.
Braus et al. (2001; 2002) Schizophrenia patients
(11 on atypical and 10 on typical)
NAA, Cho and Cr, illness duration,
duration on atypical antipsychotic
medication, WCST
Patients receiving typical antipsychotics
had lower NAA concentration than patients
receiving atypical antipsychotics.
NAA concentration was inversely
correlated with illness duration and
positively with duration on atypical
antipsychotic medication. NAA
concentration was inversely correlated
with WCST perseverative errors.
Goff et al. (2002) Schizophrenia patients (n=17;
of whom 10 switched from
conventional to olanzapine and
had MRS at baseline and 8-week follow-up).
Glu/Cr ratio, SANS Glu/Cr ratio was increased by 12.5%
(non-signiﬁcant) following switch to
olanzapine. Patients who improved
on SANS symptoms had greater
Glu/Cr ratio (45.8%) compared to
patients who deteriorated on SANS
symptoms (20.8%). No signiﬁcant
correlation between SANS total and
change in Glu/Cr ratio after switch.
Yamasue et al. (2002) Schizophrenia patients
(n=15; all on typical)
Healthy participants (n=13)
NAA, Cho and Cr; grey matter
volume; age, height, body weight,
socio-economic status, parental
socio-economic status, years of
education, PANSS, onset of illness,
illness duration, antipsychotic
medication dose.
Patients had lower NAA/Cho ratio and
greater Cho/Cr ratio compared to healthy
participants after controlling for grey
matter volume. NAA/Cho ratio was
positively correlated with grey matter
volume in patients, not healthy participants.
NAA/Cho ratio was inversely correlated
with PANSS blunted affect score.
Theberge et al. (2004, 2002) First-episode neuroleptic naïve
schizophrenia patients (n=21)
Healthy participants (n=21)
Analysis in Theberge et al. 2002
NAA, Cho, Cr, Glu, Gln, mI in left
ACC, SANS, SAPS
From Theberge et al. 2002
Patients had greater Gln concentration
compared to healthy participants.
Metabolite concentrations were not
correlated with SANS or SAPS.
Analysis in Theberge et al. 2004
NAA and Cho in left ACC DUP,
DUI, DPS
From Theberge et al. 2004
NAA concentration was positively correlated
with DUP and inversely with DPS at trend
level. Cho concentration was positively
correlated with DUP.
Theberge et al. (2003) Schizophrenia patients (n=21;
atypical n=7, both n=1,
typical n=13)
Healthy participants (n=21)
NAA, Cho, Cr, Glu, Gln, mI in
left ACC, duration of illness
Glu and Gln concentrations were greater
in patients than healthy participants. NAA
concentration was inversely correlated
with duration of positive symptoms.
Wood et al. (2007) Schizophrenia male patients
(n=15; 13 atypical, 2 medication free)
Healthy male participants (n=14)
NAA and Glx in dorsal and rostral
regions, PANSS ﬁve factors, illness
duration
Patients had lower NAA concentration
compared to healthy participants.
Right dorsal Glx was inversely correlated
with illness duration.
Ohrmann et al. (2008) Schizophrenia patients
(n=43, all on atypical)
Healthy participants (n=37)
NAA, Cho, Cr, Glx, WCST learning
potential
No difference in metabolite concentration
between patients and healthy participants.
NAA and Glx concentrations were positively
associated with WCST learning potential
Sanches et al. (2008) Schizophrenia patients (n=37)
Healthy participants (n=37)
NAA/(Cho+Cr) ratio in left and
right anterior middle frontal gyrus,
ACC and perirolandic area (reference),
basal skin conductance and skin
conductance response to auditory
stimuli of 1 s tones of 80 dB. Patients
and healthy participants classiﬁed into
skin conductance responders (2 S.D.
below mean skin conductance in healthy
participants) and non-responders.
NAA/(Cho+Cr) ratio was lower in patients
than healthy participants in the anterior
middle frontal gyrus and ACC bilaterally.
NAA/(Cho+Cr) ratio did not differ between
skin conductance response groups based on
skin conductance response to auditory stimuli.
Basal skin conductance non-responders patients
had lower NAA/(Cho+Cr) ratio than healthy
participants in left and right ACC.
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Tayoshi et al. (2009) Long-term schizophrenia (n=30;
antipsychotic medication type
not reported)
Healthy participants (n=25)
NAA, Cho, Cr, Glu, Gln, mI Gender, PANSS
total and subscales, duration of illness,
duration of therapy, antipsychotic dosage,
benzodiazepine dose
Patients had lower Glu and mI concentration
compared to healthy participants. Male
patients had lower NAA, Cr, Glu and mI
concentration than male healthy participants.
Males had greater Gln concentration compared
to females. Metabolite concentration was
not correlated with symptoms or other
clinical variables.
Ongur et al. (2009) Schizophrenia patients (n=15)
Bipolar disorder patients (n=15)
Healthy participants (n=22)
Cr in ACC (hypothesized area) and
parietal-occipital cortex (reference area),
MADRS, PANSS, YMRS
Patients had lower Cr than healthy
participants in both ACC and
parietal-occipital cortex. No signiﬁcant
correlations between Cr concentration
and clinical measures.
ACC: anterior cingulate cortex, Cho—Choline, Cr—Creatine/Phosphocreatine, DPS—duration of psychotic symptoms, DUI—duration of untreated illness, DUP—duration of untreated
psychosis, Gln—Glutamine, Glu—Glutamate, Glu/Cr ratio, SANS—Schedule for the Assessment of Negative Symptoms, Glx—Glutamate+Glutamine, MADRS—Montgomery Asberg
Depression Rating Scale, mI—myo-Inositol, NAA: N-acetyl aspartate, PANSS—Positive and Negative Syndrome Scale, SAPS: Schedule for the Assessment of Positive Symptoms,WCST—
Wisconsin Card Sorting test, YMRS—Young Mania Rating Scale.
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